Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-370 vs D745 in Healthy Volunteers
NCT03849495Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03849495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849495.